Numbers of cases, proportion, and OR for COVID-19 pneumonia in pediatric patients
| Auto-Abs (dose) . | Number of patients positive . | Proportion of patients testing positive (%) . | OR [95% CI] for COVID-19 pneumonia . | P value . |
|---|---|---|---|---|
| Anti-IFN-α2 (10 ng/ml) | 6 | 3.4 | 57 [12–560] | 3 × 10−07 |
| Anti-IFN-β (10 ng/ml) | 2 | 1.1 | 23 [3–255] | 4 × 10−03 |
| Anti-IFN-ω (10 ng/ml) | 5 | 2.8 | 9 [3–29] | 5 × 10−04 |
| Anti-IFN-α2 (100 pg/ml) | 10 | 5.5 | 30 [10–103] | 1 × 10−9 |
| Anti-IFN-ω (100 pg/ml) | 16 | 8.8 | 5 [2–8] | 7 × 10−06 |
| Anti-IFN-α2 and/or anti-IFN-ω (10 ng/ml) | 7 | 3.9 | 11 [4–32] | 2 × 10−05 |
| Anti-IFN-α2 and/or anti-IFN-β, and/or anti-IFN-ω (10 ng/ml) | 7 | 3.8 | 11 [4–29] | 3 × 10−05 |
| Anti-IFN-α2 and anti-IFN-ω (10 ng/ml) | 4 | 2.4 | 112 [12–14,991] | 9 × 10−04 |
| Anti-IFN-α2, anti-IFN-ω, and anti-IFN-β (10 ng/ml) | 2 | 1.1 | 75 [6–10,328] | 9 × 10−04 |
| Anti-IFN-α2 only (10 ng/ml) | 2 | 1.1 | 23 [3–263] | 4 × 10−03 |
| Anti-IFN-ω only (10 ng/ml) | 1 | 0.6 | 3 [0.3–12] | 3 × 10−01 |
| Anti-IFN-β only (10 ng/ml) | 0 | 0.00 | 4 [0.03–57] | 5 × 10−01 |
| Anti-IFN-α2 and/or anti-IFN-ω (100 pg/ml) | 19 | 10.4 | 5 [3–9] | 1 × 10−07 |
| Anti-IFN-α2 and anti-IFN-ω (100 pg/ml) | 7 | 3.9 | 26 [7–106] | 7 × 10−07 |
| Auto-Abs (dose) . | Number of patients positive . | Proportion of patients testing positive (%) . | OR [95% CI] for COVID-19 pneumonia . | P value . |
|---|---|---|---|---|
| Anti-IFN-α2 (10 ng/ml) | 6 | 3.4 | 57 [12–560] | 3 × 10−07 |
| Anti-IFN-β (10 ng/ml) | 2 | 1.1 | 23 [3–255] | 4 × 10−03 |
| Anti-IFN-ω (10 ng/ml) | 5 | 2.8 | 9 [3–29] | 5 × 10−04 |
| Anti-IFN-α2 (100 pg/ml) | 10 | 5.5 | 30 [10–103] | 1 × 10−9 |
| Anti-IFN-ω (100 pg/ml) | 16 | 8.8 | 5 [2–8] | 7 × 10−06 |
| Anti-IFN-α2 and/or anti-IFN-ω (10 ng/ml) | 7 | 3.9 | 11 [4–32] | 2 × 10−05 |
| Anti-IFN-α2 and/or anti-IFN-β, and/or anti-IFN-ω (10 ng/ml) | 7 | 3.8 | 11 [4–29] | 3 × 10−05 |
| Anti-IFN-α2 and anti-IFN-ω (10 ng/ml) | 4 | 2.4 | 112 [12–14,991] | 9 × 10−04 |
| Anti-IFN-α2, anti-IFN-ω, and anti-IFN-β (10 ng/ml) | 2 | 1.1 | 75 [6–10,328] | 9 × 10−04 |
| Anti-IFN-α2 only (10 ng/ml) | 2 | 1.1 | 23 [3–263] | 4 × 10−03 |
| Anti-IFN-ω only (10 ng/ml) | 1 | 0.6 | 3 [0.3–12] | 3 × 10−01 |
| Anti-IFN-β only (10 ng/ml) | 0 | 0.00 | 4 [0.03–57] | 5 × 10−01 |
| Anti-IFN-α2 and/or anti-IFN-ω (100 pg/ml) | 19 | 10.4 | 5 [3–9] | 1 × 10−07 |
| Anti-IFN-α2 and anti-IFN-ω (100 pg/ml) | 7 | 3.9 | 26 [7–106] | 7 × 10−07 |